HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Asensus Surgical (AMEX:ASXC) with a Buy and maintains $3 price target.
Goldman Sachs Maintains Neutral Rating for LifeStance Health Gr: Here’s What You Need To Know
Goldman Sachs has decided to maintain its Neutral rating of LifeStance Health Gr (NASDAQ:LFST) and lower its price…